| Original language | English (US) |
|---|---|
| Pages (from-to) | 1032-1034 |
| Number of pages | 3 |
| Journal | Journal of the American College of Cardiology |
| Volume | 79 |
| Issue number | 10 |
| DOIs | |
| State | Published - Mar 15 2022 |
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Journal of the American College of Cardiology, Vol. 79, No. 10, 15.03.2022, p. 1032-1034.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Assessment of Disease Status and Treatment Response With Artificial Intelligence−Enhanced Electrocardiography in Obstructive Hypertrophic Cardiomyopathy
AU - PIONEER-OLE Investigators
AU - Tison, Geoffrey H.
AU - Siontis, Konstantinos C.
AU - Abreau, Sean
AU - Attia, Zachi
AU - Agarwal, Priyanka
AU - Balasubramanyam, Aarthi
AU - Li, Yunfan
AU - Sehnert, Amy J.
AU - Edelberg, Jay M.
AU - Friedman, Paul A.
AU - Olgin, Jeffrey E.
AU - Noseworthy, Peter A.
N1 - Funding Information: The Tison lab received funding from MyoKardia, Inc, a wholly owned subsidiary of Bristol Myers Squibb to support this analysis. The work to derive the Mayo Clinic AI-ECG algorithm was funded by the Louis V. Gerstner, Jr. Fund at Vanguard Charitable. The PIONEER-OLE study was funded by MyoKardia. Drs Siontis, Attia, Friedman, and Noseworthy are coinventors of the Mayo Clinic AI-ECG algorithm used in this work. Dr Tison was supported by the National Heart, Lung, and Blood Institute (K23HL135274); has received research grants from General Electric, Janssen Pharmaceuticals and MyoKardia, Inc, a wholly owned subsidiary of Bristol Myers Squibb; and has received consulting fees from MyoKardia. Drs Agarwal, Balasubramanyam, Sehnert, and Edelberg hold stock and stock options from MyoKardia. Dr Olgin has received research funding from the NIH (U2CEB021881) and from Samsung and iBeat. Dr Noseworthy has received research funding from the National Institutes of Health, including the National Heart, Lung, and Blood Institute, and the National Institute on Aging (NIA), the Agency for Healthcare Research and Quality, the U.S. Food and Drug Administration (FDA), and the American Heart Association; has been a study investigator in an ablation trial sponsored by Medtronic; and has been involved in a potential equity/royalty relationship with AliveCor, together with the Mayo Clinic. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. The authors thank the patients and their families, the investigators, and the clinical study teams for making this study possible. Editorial support was provided by Kim Fuller, PhD (Cello Health Communications/SciFluent), financially supported by MyoKardia, Inc, a wholly owned subsidiary of Bristol Myers Squibb.
PY - 2022/3/15
Y1 - 2022/3/15
UR - http://www.scopus.com/inward/record.url?scp=85125334365&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125334365&partnerID=8YFLogxK
U2 - 10.1016/j.jacc.2022.01.005
DO - 10.1016/j.jacc.2022.01.005
M3 - Letter
C2 - 35272798
AN - SCOPUS:85125334365
SN - 0735-1097
VL - 79
SP - 1032
EP - 1034
JO - Journal of the American College of Cardiology
JF - Journal of the American College of Cardiology
IS - 10
ER -